Rheumatology Genomic Test Developer Exagen Diagnostics Raises $5.3M | GenomeWeb

NEW YORK (GenomeWeb News) – Exagen Diagnostics, which develops genomic tests aimed at rheumatology, announced on Monday the completion of a financing round that raised $5.3 million.

The funding will be used to expand the market for the Albuquerque, NM-based firm's brands and further development of near-term pipeline products, it said. Exagen plans to expand its three marketed rheumatology brands — Avise SLE, Avise PG, and Avise MCV — and other products that will help physicians diagnose and treat rheumatologic disorders, company President and CEO Ron Rocca said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.